Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

996 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Rational discovery of molecular glue degraders via scalable chemical profiling.
Mayor-Ruiz C, Bauer S, Brand M, Kozicka Z, Siklos M, Imrichova H, Kaltheuner IH, Hahn E, Seiler K, Koren A, Petzold G, Fellner M, Bock C, Müller AC, Zuber J, Geyer M, Thomä NH, Kubicek S, Winter GE. Mayor-Ruiz C, et al. Among authors: geyer m. Nat Chem Biol. 2020 Nov;16(11):1199-1207. doi: 10.1038/s41589-020-0594-x. Epub 2020 Aug 3. Nat Chem Biol. 2020. PMID: 32747809 Free PMC article.
Publisher Correction: Rational discovery of molecular glue degraders via scalable chemical profiling.
Mayor-Ruiz C, Bauer S, Brand M, Kozicka Z, Siklos M, Imrichova H, Kaltheuner IH, Hahn E, Seiler K, Koren A, Petzold G, Fellner M, Bock C, Müller AC, Zuber J, Geyer M, Thomä NH, Kubicek S, Winter GE. Mayor-Ruiz C, et al. Among authors: geyer m. Nat Chem Biol. 2021 Mar;17(3):361. doi: 10.1038/s41589-021-00735-4. Nat Chem Biol. 2021. PMID: 33452497 No abstract available.
Discovery and resistance mechanism of a selective CDK12 degrader.
Jiang B, Gao Y, Che J, Lu W, Kaltheuner IH, Dries R, Kalocsay M, Berberich MJ, Jiang J, You I, Kwiatkowski N, Riching KM, Daniels DL, Sorger PK, Geyer M, Zhang T, Gray NS. Jiang B, et al. Among authors: geyer m. Nat Chem Biol. 2021 Jun;17(6):675-683. doi: 10.1038/s41589-021-00765-y. Epub 2021 Mar 22. Nat Chem Biol. 2021. PMID: 33753926 Free PMC article.
Recessive NLRC4-Autoinflammatory Disease Reveals an Ulcerative Colitis Locus.
Steiner A, Reygaerts T, Pontillo A, Ceccherini I, Moecking J, Moghaddas F, Davidson S, Caroli F, Grossi A, Castro FFM, Kalil J, Gohr FN, Schmidt FI, Bartok E, Zillinger T, Hartmann G, Geyer M, Gattorno M, Mendonça LO, Masters SL. Steiner A, et al. Among authors: geyer m. J Clin Immunol. 2021 Nov 16. doi: 10.1007/s10875-021-01175-4. Online ahead of print. J Clin Immunol. 2021. PMID: 34783940
Phase II biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.
Moskowitz AJ, Ghione P, Jacobsen ED, Ruan J, Schatz JH, Noor SJ, Myskowski PL, Vardhana SA, Ganesan N, Hancock H, Davey T, Perez L, Ryu S, Santarosa AM, Dowd J, Obadi O, Pomerantz LD, Yi N, Sohail S, Galasso N, Neuman R, Liotta B, Blouin W, Baik J, Geyer MB, Noy A, Straus DJ, Kumar P, Dogan A, Hollmann TJ, Drill E, Rademaker J, Schöder H, Inghirami GG, Weinstock DM, Horwitz SM. Moskowitz AJ, et al. Among authors: geyer mb. Blood. 2021 Oct 15:blood.2021013379. doi: 10.1182/blood.2021013379. Online ahead of print. Blood. 2021. PMID: 34653242
996 results